Broadening the evidence base for evidence-based guidelines: A research agenda based on the work of the U.S. preventive services task force

American Journal of Preventive Medicine

Volumn 14, Issue 4, 1998, Pages 335-344

  Atkins, David ^a   DiGuiseppi, Carolyn G ^a,b  

^a AGENCY FOR HEALTHCARE RESEARCH AND QUALITY   (United States)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Behavior change; Counseling; Intervention studies; Meta analysis; Patient participation; Periodicity; Risk assessment

Indexed keywords

CLINICAL RESEARCH; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; EVIDENCE BASED MEDICINE; HUMAN; META ANALYSIS; PATIENT COUNSELING; PRACTICE GUIDELINE; PREVENTIVE HEALTH SERVICE; PRIMARY MEDICAL CARE; QUALITY CONTROL; REVIEW; RISK ASSESSMENT; SCREENING TEST;

EID: 0032077319     PISSN: 07493797     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0749-3797(97)00058-5     Document Type: Article

References (78)

1. 1. Eddy DM. A manual for assessing health practices and designing practice policies: the explicit approach. Philadelphia: American College of Physicians; 1992.
2. 2. U.S. Preventive Services Task Force. Guide to clinical preventive services, 2nd ed. Baltimore: Williams and Wilkins; 1996.
3. 3. Canadian Task Force on the Periodic Health Examination. The Canadian guide to clinical preventive health care. Ottawa: Canada Communication Group; 1994.
4. 4. Eddy DM, ed. Common screening tests. Philadelphia: American College of Physicians; 1991.
5. 5. U.S. Preventive Services Task Force. Guide to clinical preventive services: an assessment of the effectiveness of 169 interventions. Baltimore, Maryland: Williams & Wilkins; 1989.
6. 6. McGinnis JM, Foege WH. Actual causes of death in the United States. JAMA 1993;270:2207-12.
7. 7. Glanz K, Lewis FM, Rimer BK, eds. Health behavior and health education: theory, research and practice. San Francisco: Jossey-Bass; 1990.
8. 8. Green LW, Kreuter MW. Health promotion planning: an educational and environmental approach. 2nd ed. Mountain View, California: Mayfield Publishing Co.; 1991.
9. 9. Institute of Medicine. The best intentions: unintended pregnancy and the well-being of children and families. Brown SS, Eisenberg L, eds. Washington, DC: National Academy Press; 1995.
10. 10. Institute of Medicine. AIDS and behavior: an integrated approach. Auerbach JD, Wypijewska C, Brodie HKH, eds. Washington, DC: National Academy Press; 1994.
11. 11. Cohen DA, MacKinnon DP, Dent C, et al. Group counseling at STD clinics to promote use of condoms. Public Health Rep 1992;107:727-31.
12. 12. Rickert VI, Gottlieb AA, Jay MS. Is AIDS education related to condom acquisition? Clin Pediatr (Phila) 1992;31:205-10.
13. 13. Caggiula AW, Christakis G, Farrand M, et al. The Multiple Risk Factor Intervention Trial (MRFIT). IV. Intervention on blood lipids. Prev Med 1981;10:443-75.
14. 14. The Writing Group for the DISC Collaborative Research Group. Efficacy and safety of lowering dietary intake of fat and cholesterol in children with elevated low-density lipoprotein cholesterol: the Dietary Intervention Study in Children (DISC). JAMA 1995;273:1429-35.
15. 15. Kottke TE, Battista RN, DeFriese GH, et al. Attributes of successful smoking cessation interventions in medical practice: a meta-analysis of 39 controlled trials. JAMA 1988;259:2882-9.
16. 16. Bien TH, Miller WR, Tonigan JS. Brief interventions for alcohol problems: a review. Addiction 1993;88:315-36.
17. 17. Bass J, Christoffel K, Widome M, et al. Childhood injury prevention counseling in primary care settings. Pediatrics 1993;92:544-53.
18. 18. Ramsay LE, Yeo WW, Jackson PR. Dietary reduction of serum cholesterol concentration: time to think again. BMJ 1991;303:953-7.
19. 19. Gibbins RL, Riley M, Brimble P. Effectiveness of programme for reducing cardiovascular risk for men in one general practice. BMJ 1993;306:1652-6.
20. 20. Neil HAW, Roe L, Godlee RJP, et al. Randomised trial of lipid lowering dietary advice in general practice: the effects on serum lipids, lipoproteins, and antioxidants. BMJ 1995;310:569-73.
21. 21. Ammerman A, Caggiula A, Elmer PJ, et al. Putting medical practice guidelines into practice: the cholesterol model. Am J Prev Med 1994;10:209-16.
22. 22. Caggiula AW, Watson JE, Kuller LH, et al. Cholesterol-Lowering Intervention Program: effect of the Step 1 diet in community office practices. Arch Intern Med 1996; 156:1205-13.
23. 23. Schectman G, Wolff N, Byrd JC, et al. Physician extenders for cost-effective management of hypercholesterolemia. J Gen Intern Med 1996;11:277-86.
24. 24. Higgins DL, Galavotti C, O'Reilly KR, et al. Evidence for the effects of HIV antibody counseling and testing on risk behaviors. JAMA 1991;266:2419-29.
25. 25. Slater M. Health for our children: achieving appropriate health care for black and minority ethnic children and their families. London: Action for Sick Children, 1993.
26. 26. Department of Health and Human Services. Preventing tobacco use among young people: a report of the Surgeon General. Washington, DC: U.S. Government Printing Office; 1994; Publication no. S/N 017-001-00491-0.
27. 27. Kerlikowske K, Grady D, Rubin SM, et al. Efficacy of screening mammography: a meta-analysis. JAMA 1995; 273:149-54.
28. 28. Selby JV, Friedman GD, Quesenberry CP, et al. A case-control study of screening sigmoidoscopy and mortality from colorectal cancer. N Engl J Med 1992;326:653-7.
29. 29. Pauker SG, Kassirer JP. Contentious screening decisions: does the choice matter? New Engl J Med 1997;336:1243-4.
30. 30. Col NF, Eckman MH, Karas RH, et al. Patient-specific decisions about hormone replacement therapy in postmenopausal women. JAMA 1997;277:1140-7.
31. 31. Spencer K, Carpenter P. Prospective study of prenatal screening for Down's syndrome with free β human chorionic gonadotrophin. BMJ 1993;307:764-9.
32. 32. Haddow JE, Palomaki GE, Knight GJ, et al. Prenatal screening for Down's syndrome with use of maternal serum markers [see comments]. N Engl J Med 1992;327:588-93.
33. 33. Abuelo D, Hopmann MR, Barsel-Bowers G, et al. Anxiety in women with low maternal serum alpha-fetoprotein screening results. Prenat Diagn 1991;11:381-5.
34. 34. Smith DS, Catalona WJ, Herschman JD. Longitudinal screening for prostate cancer with prostate-specific antigen. JAMA 1996;276:1309-15.
35. 35. Wennberg JE. Improving the decision-making process. Health Aff (Millwood) 1988;7:99-106.
36. 36. Greenfield S, Kaplan SH, Ware JE Jr. Expanding patient involvement in care: effects on patient outcomes. Ann Intern Med 1985;102:520-8.
37. 37. Ernster VL. Mammography screening for women aged 40 through 49: a guidelines saga and a clarion call for informed decision making. Am J Public Health 1997;87: 1103-6.
38. 38. Handley MR, Stuart ME. The use of prostate specific antigen for prostate cancer screening: a managed care perspective. J Urol 1994;152:1689-92.
39. 39. Flood AB, Wennberg JE, Nease RF, et al. The importance of patient preferences in the decision to screen for prostate cancer. J Gen Intern Med 1996;11:342-9.
40. 40. Chan E, Sulmasy D. What do patients need to know about PSA screening? [abstract] J Gen Intern Med 1996; 11 (Suppl 1):114.
41. 41. Stergachis A, Scholes D, Heidrich FE, et al. Selective screening for Chlamydia trachomatis infection in a primary care population of women. Am J Epidemiol 1993;138: 143-53.
42. 42. Scholes D, Stergachis A, Heidrich FE, et al. Prevention of pelvic inflammatory disease by screening for cervical chlamydial infection. N Engl J Med 1996;334:1362-6.
43. 43. Krahn MD, Mahoney JE, Eckman MH, et al. Screening for prostate cancer; a decision analytic review. JAMA 1994; 272:773-80.
44. 44. Coley CM, Barry MJ, Fleming C, et al. Early detection of prostate cancer. Part II: Estimating the risks, benefits, and costs. Ann Intern Med 1997;126:468-79.
45. 45. Gold MR, Siegel JE, Russell LB, Weinstein MC. Cost-effectiveness in health and medicine. New York: Oxford University Press; 1996.
46. 46. Gray JAM. Evidence-based health care: how to make health policy and management decisions. London: Churchill Livingstone; 1996.
47. 47. Lieu TA, Cochi SL, Black SB, et al. Cost-effectiveness of a routine varicella vaccination program for US children. JAMA 1994;271:375-81.
48. 48. Winawer SJ, Fletcher RH, Miller L, et al. Colorectal cancer screening: clinical guidelines and rationale. Gastroenterology 1997;112:594-642.
49. 49. Johannesson M, Jonsson B, Kjekshus J, et al. Cost effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease. Scandinavian Simvastatin Survival Study Group. N Engl J Med 1997;336:332-6.
50. 50. Centers for Disease Control and Prevention. Screening young children for lead poisoning: guidance for state and local public health officials. Atlanta, Georgia: Centers for Disease Control and Prevention; 1997.
51. 51. Lee TT, Solomon NA, Heidenreich PA, et al. Cost-effectiveness of screening for carotid artery stenosis in asymptomatic persons. Ann Intern Med 1997;126:337-46.
52. 52. Omenn GS, Goodman GE, Thornquist MD, et al. Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. N Engl J Med 1996; 334:1150-5.
53. 53. Hennekens CH, Buring JE, Manson JE, et al. Lack of effect of long-term supplementation with beta-carotene on the incidence of malignant neoplasms and cardiovascular disease. N Engl J Med 1996;334:1145-9.
54. 54. Woolf SH, DiGuiseppi CG, Atkins D, Kamerow DB. Developing evidence-based clinical practice guidelines: lessons learned by the U.S. Preventive Services Task Force. Annu Rev Public Health 1996;17:511-38.
55. 55. The Lipid Research Clinics Coronary Primary Prevention Project. 1. Reduction in incidence of coronary heart disease. JAMA 1984;251:351-64.
56. 56. Frick MH, Elo O, Haapa K, et al. Helsinki Heart Study: primary prevention trial with gemfibrozil in middleaged men with dylipidemia. N Engl J Med 1987;317: 1237-45.
57. 57. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995;333:1301-7.
58. 58. Office on Smoking and Health, Centers for Disease Control. The health benefits of smoking cessation. Rockville, Maryland: U.S. Department of Health and Human Services; 1990; DHHS Publication No. (CDC) 90-8416.
59. 59. Andrade SE, Walker AM, Gottlieb LK, et al. Discontinuation of antihyperlipidemic drugs: do rates reported in clinical trials reflect rates in primary care settings? N Engl J Med 1995;332:1125-31.
60. 60. Litwin MS, Hays RD, Fink A, et al. Quality-of-life outcomes in men treated for localized prostate cancer. JAMA 1995;273:129-35.
61. 61. Gann PH, Hennekens CH, Stampfer M. A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer. JAMA 1995;273:289-94.
62. 62. Kleijnen J, Gotzsche P, Kunz RA, et al. So what's so special about randomisation? In: Maynard A, Chalmers I, eds. Non-random reflections on health services research: on the 25th anniversary of Archie Cochrane's Effectiveness and Efficiency. London: BMJ Publishing Group; 1997:93-106.
63. 63. Thompson RS, Rivara FP, Thompson DC. A case-control study of the effectiveness of bicycle safety helmets. N Engl J Med 1989;320:1361-7.
64. 64. Thomas S, Acton C, Nixon J, et al. Effectiveness of bicycle helmets in preventing head injury in children: case-control study. BMJ 1994;308:173-6.
65. 65. Chalmers TC. Implications of meta-analysis: need for a new generation of randomized control trials. In: McCormick KA, Moore SR, Siegel RA, eds. Clinical practice guideline development: methodology perspectives. Rockville, Maryland: U.S. Department of Health and Human Services; 1994; AHCPR Pub. No. 95-0009.
66. 66. LeLorier J, Gregoire G, Benhaddad A, et al. Discrepancies between meta-analyses and subsequent large randomized, controlled trials. N Engl J Med 1997;337:536-42.
67. 67. Hedges LV. Combining estimates across studies: metaanalysis of research. In: McCormick KA, Moore SR, Siegel RA, eds. Clinical practice guideline development: methodology perspectives. Rockville, MD: U.S. Department of Health and Human Services; 1994; AHCPR Pub. No. 95-0009.
68. 68. Mulrow CD, Cook DJ, Davidoff F. Systematic reviews: critical links in the great chain of evidence. Ann Intern Med 1997;126:389-91.
69. 69. Bero L, Rennie D. The Cochrane Collaboration. Preparing, maintaining, and disseminating systematic reviews of the effects of health care. JAMA 1995;274:1935-8.
70. 70. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy. I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994;308:81-106.
71. 71. Buchner DM, Hornbrook MC, Kutner NG, et al. Development of the common data base for the FICSIT trials. J Am Geriatr Soc 1993;41:297-308.
72. 72. Ory MG, Schechtman KB, Miller JP, et al. Frailty and injuries in later life: the FICSIT trials. J Am Geriatr Soc 1993;41:283-96.
73. 73. Province MA, Hadley EC, Hornbrook MC, et al. The effects of exercise on falls in elderly patients: a pre-planned meta-analysis of the FICSIT trials. JAMA 1995; 273:1341-7.
74. 74. Pocock SJ, Smith M, Baghurst P. Environmental lead and children's intelligence: a systematic review of the epidemiological evidence. Br Med J 1994;309:1189-97.
75. 75. Begg C, Cho M, Eastwood S, et al. Improving the quality of reporting of randomized controlled trials. The CONSORT statement. JAMA 1996;276:637-9.
76. 76. Grimshaw JM, Russell IT. Effect of clinical guidelines on medical practice: a systematic review of rigorous evaluations. Lancet 1993;342:1317-22.
77. 77. Implementing clinical practice guidelines: can guidelines be used to improve clinical practice? Effective Health Care 1994;8:1-12.
78. 78. National Committee for Quality Assurance. Health Plan Employer Data and Information Set (HEDIS 3.0). Washington, DC: NCQA; 1997.